Related references
Note: Only part of the references are listed.Epigenetic tools in potential anticancer therapy
Katarina Sebova et al.
ANTI-CANCER DRUGS (2010)
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Pierre Fenaux et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine
Irina Daurkin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
John F. Seymour et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2010)
Epigenetic Changes in the Myelodysplastic Syndrome
Jean-Pierre Issa
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Jiahuai Tan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Epigenetic modifications in AML and MDS
Mohammad Mahmud et al.
LEUKEMIA RESEARCH (2010)
Histone deacetylase inhibitors: A new perspective for the treatment of leukemia
Ana Lucia Abujamra et al.
LEUKEMIA RESEARCH (2010)
Histone deacetylases and epigenetic therapies of hematological malignancies
Ciro Mercurio et al.
PHARMACOLOGICAL RESEARCH (2010)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Superior Outcome With Hypomethylating Therapy in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome and Chromosome 5 and 7 Abnormalities
Farhad Ravandi et al.
CANCER (2009)
Nuclear PLC Beta 1 is required for 3T3-L1 adipocyte differentiation and regulates expression of the cyclin D3-cdk4 complex
Simon J. O'Carroll et al.
CELLULAR SIGNALLING (2009)
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
Maria Teresa Voso et al.
CLINICAL CANCER RESEARCH (2009)
Phosphoinositide-Phospholipase C β1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia
Matilde Y. Follo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents
Lewis R. Silverman
LEUKEMIA RESEARCH (2009)
In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?
Steven D. Gore
LEUKEMIA RESEARCH (2009)
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS
Matilde Y. Follo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Current status of epigenetic treatment in myelodysplastic syndromes
Andrea Kuendgen et al.
ANNALS OF HEMATOLOGY (2008)
Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers
Fadi Braiteh et al.
CLINICAL CANCER RESEARCH (2008)
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
J. A. McCubrey et al.
LEUKEMIA (2008)
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism
F. Chiarini et al.
LEUKEMIA (2008)
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
L. S. Steelman et al.
LEUKEMIA (2008)
PI-PLC beta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes
M. Y. Follo et al.
LEUKEMIA (2008)
Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia
Yun-Chih Cheng et al.
LEUKEMIA RESEARCH (2007)
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation
Matilde Y. Follo et al.
CANCER RESEARCH (2007)
Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines
Tobias Berg et al.
LEUKEMIA RESEARCH (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
A unique function for cyclin D3 in early B cell development
AB Cooper et al.
NATURE IMMUNOLOGY (2006)
Effects of 5-aza-2 '-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells
Y Guo et al.
LEUKEMIA (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies
KN Bhalla
JOURNAL OF CLINICAL ONCOLOGY (2005)
Histone deacetylase is a target of valproic acid-mediated cellular differentiation
N Gurvich et al.
CANCER RESEARCH (2004)
The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman et al.
BLOOD (2002)
Cell cycle control genes and hematopoietic cell differentiation
Y Furukawa
LEUKEMIA & LYMPHOMA (2002)
A role for nuclear phospholipase Cβ1 in cell cycle control
I Faenza et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
